ReviewCureus2025
Hepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic Ketamine Toxicity Involving both Urinary and Hepatobiliary Systems.Journal of the Belgian Society of Radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine has been utilized in various medical contexts, particularly for its effects on the nervous system. Over time, its applications have expanded beyond its initial use, with emerging interest in its potential to influence mood and cognition. In certain clinical populations, it has been associated with a rapid reduction in depressive symptoms and suicidal thoughts, particularly when conventional treatments have proven insufficient. Despite these promising therapeutic effects, concerns remain regarding possible adverse consequences, including those related to liver and biliary function. This review explores the current understanding of how ketamine use may impact hepatic and biliary health, with a focus on observed complications, possible underlying mechanisms, clinical manifestations, and available management strategies. A structured examination of existing medical literature was conducted, drawing from multiple scientific sources to identify research on ketamine's effects on liver and biliary function. Studies involving human participants were included, particularly those documenting changes in liver enzyme levels, disruptions in bile flow, and structural alterations in the biliary system. The selection criteria emphasized original investigations, case reports, and clinical evaluations published in peer-reviewed sources. Findings indicate that ketamine exposure has been associated with a spectrum of liver and biliary changes, ranging from mild laboratory abnormalities to more serious conditions that require medical intervention. Several possible biological mechanisms have been proposed, including effects on bile flow regulation, oxidative stress, and toxicity affecting liver function. Notably, discontinuing ketamine use has been linked to improvements in many cases, and various treatment approaches, including supportive care and specific pharmacologic interventions, have been explored to alleviate symptoms. As ketamine continues to be incorporated into diverse therapeutic settings, understanding its full range of effects remains crucial. Further research is needed to clarify how these biological changes occur, identify individuals who may be more susceptible, and develop strategies to ensure safer use across different clinical and nonclinical populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.